Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients

J Thorac Oncol. 2018 Nov;13(11):e215-e217. doi: 10.1016/j.jtho.2018.05.033. Epub 2018 Jun 6.

Authors

Arthur Geraud¹, Laura Mezquita¹, Frederic Bigot¹, Caroline Caramella², David Planchard¹, Cecile Le Pechoux³, Benjamin Besse⁴

Affiliations

¹ Medical Oncology Department, Gustave Roussy, Villejuif, France.
² Radiology Department, Gustave Roussy, Villejuif, France.
³ Radiotherapy Department, Gustave Roussy, Villejuif, France.
⁴ Medical Oncology Department, Gustave Roussy, Villejuif, France. Electronic address: benjamin.besse@gustaveroussy.fr.

PMID: 29885478
DOI: 10.1016/j.jtho.2018.05.033

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Carcinoma, Non-Small-Cell Lung / complications*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Meningeal Neoplasms / secondary*
Middle Aged
Organophosphorus Compounds / adverse effects*
Organophosphorus Compounds / pharmacology
Organophosphorus Compounds / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / pharmacology
Pyrimidines / therapeutic use

Substances

Organophosphorus Compounds
Pyrimidines
brigatinib